Nontoxicity Endpoints in Phase I Trial Designs for Targeted, Non-Cytotoxic Agents
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/96/13/977/7685490/djh208.pdf
Reference9 articles.
1. Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
2. Novel endpoints and design of early clinical trials
3. Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?
4. Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials;Trials;2023-11-21
2. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy;Contemporary Clinical Trials;2023-04
3. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose;Contemporary Clinical Trials;2023-04
4. CWL: A conditional weighted likelihood method to account for the delayed joint toxicity–efficacy outcomes for phase I/II clinical trials;Statistical Methods in Medical Research;2020-12-21
5. A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes;Biometrics;2020-08-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3